Report: Medtech M&A exits don’t hinge on FDA approval

July 31, 2014 by Arezu Sarvestani

Medical device startups face significant headwinds in finding funding and getting to an exit, but at least prospective buyers are a little more willing to gamble on companies that haven’t yet made it through the FDA.

Report: Medtech M&A no longer hinges on FDA approval
The funding environment for medical device startups isn’t a pretty scene, but there is a ray of sunshine through the gloom: lack of FDA approval is no longer a deal-breaker for a big exit.

In 2013 a few medtech companies managed “big exit M&A” deals (those worth $50 million or more) without having reached the FDA’s brass ring, according to a new report from Silicon Valley Bank.



Josh Sandberg

Josh Sandberg is the President of Ortho Sales Partners and Partner for The De Angelis Group. He also serves as Co-Founder and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *